
-
Dermata Therapeutics NASDAQ:DRMA Dermata is a clinical-stage biotechnology company focused on making major advancements in the treatment of medical and aesthetic skin diseases and conditions. Dermata has a team of experienced individuals who are currently focused on progressing two programs for the treatment of acne, psoriasis, rosacea and aesthetic indications.
Location: | Website: www.dermatarx.com | Industry: Medicinal and Botanical Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
2.052M
Cash
3.162M
Avg Qtr Burn
-2.791M
Short % of Float
4.73%
Insider Ownership
23.27%
Institutional Own.
0.84%
Qtr Updated
12/31/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
XYNGARI™ (formerly DMT310) Details Acne vulgaris, Acne | Phase 3 Initiation | |
Xyngari + Daxxify Details Primary axillary hyperhidrosis | Phase 2a Initiation | |
XYNGARI™ (formerly DMT310) Details Papulopustular rosacea | Failed Discontinued | |
XYNGARI™ (formerly DMT310) Details Psoriasis | Failed Discontinued |